NCT00685022 - Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

August 31, 2003

Study Completion Date

August 31, 2003

Conditions

Asthma

Interventions

DRUG

Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI

"1. Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)~2. Arm #A~3. Xopenex HFA MDI, albuterol HFA MDI"

DRUG

Racemic Albuterol followed by levalbuterol HFA MDI

"1. Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)~2. Arm #B~3. albuterol HFA MDI, Xopenex HFA MDI"

Trial Locations (3)

Unknown

Encinitas

North Dartmouth

St Louis

All Listed Sponsors

lead

Sumitomo Pharma America, Inc.

INDUSTRY